Highly sulfated K5 Escherichia coli polysaccharide derivatives inhibit respiratory syncytial virus infectivity in cell lines and human tracheal-bronchial histocultures

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 8, 2014, Pages 4782-4794

  Cagno, Valeria ^a   Donalisio, Manuela ^a   Civra, Andrea ^a   Volante, Marco ^b   Veccelli, Elena ^c   Oreste, Pasqua ^c   Rusnati, Marco ^d   Lembo, David ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c Glycores 2000   (Italy)

^d UNIVERSITY OF BRESCIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; BACTERIAL POLYSACCHARIDE; CAPSULAR POLYSACCHARIDE K5; HEPARIN;

BACTERIAL CAPSULE; BRONCHUS; CELL LINE; CELL SURVIVAL; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; EPITHELIUM CELL; ESCHERICHIA COLI; GIANT CELL; HUMAN; HUMAN RESPIRATORY SYNCYTIAL VIRUS; ISOLATION AND PURIFICATION; PATHOLOGY; PHYSIOLOGY; TISSUE CULTURE TECHNIQUE; TRACHEA; ULTRASTRUCTURE; VIRAL PLAQUE ASSAY; VIROLOGY; VIRUS ATTACHMENT; VIRUS LOAD; VIRUS REPLICATION;

ANTIVIRAL AGENTS; BACTERIAL CAPSULES; BRONCHI; CELL LINE; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EPITHELIAL CELLS; ESCHERICHIA COLI; GIANT CELLS; HEPARIN; HUMANS; POLYSACCHARIDES, BACTERIAL; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; TISSUE CULTURE TECHNIQUES; TRACHEA; VIRAL LOAD; VIRAL PLAQUE ASSAY; VIRUS ATTACHMENT; VIRUS REPLICATION;

EID: 84905364625     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02594-14     Document Type: Article

References (69)

1. Collins PL, Crowe JE, Jr. 2007. Respiratory syncytial virus and metapneumovirus, p 1601-1646. In Knipe DM, Howley PM (ed), Fields virology, 5th ed. Lippincott Williams and Wilkins, Philadelphia, PA.
2. Shay DK, Holman RC, Roosevelt GE, Clarke MJ, Anderson LJ. 2001. Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979-1997. J. Infect. Dis. 183:16-22. http://dx.doi.org/10.1086/317655.
3. Falsey AR, Formica MA, Hennessey PA, Criddle MM, Sullender WM, Walsh EE. 2006. Detection of respiratory syncytial virus in adults with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 173:639-643. http://dx.doi.org/10.1164/rccm.200510-1681OC.
4. Leader S, Kohlhase K. 2002. Respiratory syncytial virus-coded pediatric hospitalizations, 1997 to 1999. Pediatr. Infect. Dis. J. 21:629-632. http://dx.doi.org/10.1097/00006454-200207000-00005.
5. World Health Organization. 2009. Initiative for vaccine research (IVR). Acute respiratory infections. World Health Organization, Geneva, Switzerland. http://www.who.int/vaccine-research/diseases/ari/en/.
6. Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA, Auinger P, Griffin MR, Poehling KA, Erdman D, Grijalva CG, Zhu Y, Szilagyi P. 2009. The burden of respiratory syncytial virus infection in young children. N. Engl. J. Med. 360:588-598. http://dx.doi.org/10.1056/NEJMoa0804877.
7. Pelletier AJ, Mansbach JM, Camargo CA, Jr. 2006. Direct medical costs of bronchiolitis hospitalizations in the United States. Pediatric. 118:2418-2423. http://dx.doi.org/10.1542/peds.2006-1193.
8. Corsello G. 2007. Bronchiolitis: the new American Academy of Pediatrics guidelines. J. Chemother. 19(Suppl 2):12-14.
9. Castilow EM, Varga SM. 2008. Overcoming T cell-mediated immunopathology to achieve safe RSV vaccination. Future Virol. 3:445-454. http://dx.doi.org/10. 2217/17460794.3.5.445.
10. American Academy of Pediatrics Subcommittee on Diagnosis and Management of Bronchiolitis. 2006. Diagnosis and management of bronchiolitis. Pediatric. 118:1774-1793. http://dx.doi.org/10.1542/peds.2006-2223.
11. Leyssen P, De Clercq E, Neyts J. 2008. Molecular strategies to inhibit the replication of RNA viruses. Antiviral Res. 78:9-25. http://dx.doi.org/10. 1016/j.antiviral.2008.01.004.
12. Sidwell RW, Barnard DL. 2006. Respiratory syncytial virus infections: recent prospects for control. Antiviral Res. 71(2-3):379-390. http://dx.doi.org/10.1016/j.antiviral.2006.05.014.
13. Johnson S, Oliver C, Prince GA, Hemming VG, Pfarr DS, Wang SC, Dormitzer M, O'Grady J, Koenig S, Tamura JK, Woods R, Bansal G, Couchenour D, Tsao E, Hall WC, Young JF. 1997. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J. Infect. Dis. 176:1215-1224. http://dx.doi.org/10.1086/514115.
14. Wu H, Pfarr DS, Losonsky GA, Kiener PA. 2008. Immunoprophylaxis of RSV infection: advancing from RSV-IGIV to palivizumab and motavizumab. Curr. Top. Microbiol. Immunol. 317:103-123.
15. Welliver RC. 2010. Pharmacotherapy of respiratory syncytial virus infection. Curr. Opin. Pharmacol. 10:289-293. http://dx.doi.org/10.1016/j.coph. 2010.04.013.
16. van Drunen Littel-van den Hurk S, Watkiss ER. 2012. Pathogenesis of respiratory syncytial virus. Curr. Opin. Virol. 2:300-305. http://dx.doi.org/10. 1016/j.coviro.2012.01.008.
17. King, JC, Jr. 1997. Community respiratory viruses in individuals with human immunodeficiency virus infection. Am. J. Med. 102:19-24. http://dx.doi.org/10.1016/S0002-9343(97)80005-8.
18. Crim RL, Audet SA, Feldman SA, Mostowski HS, Beeler JA. 2007. Identification of linear heparin-binding peptides derived from human respiratory syncytial virus fusion glycoprotein that inhibit infectivity. J. Virol. 81:261-271. http://dx.doi.org/10.1128/JVI.01226-06.
19. Feldman SA, Audet S, Beeler JA. 2000. The fusion glycoprotein of human respiratory syncytial virus facilitates virus attachment and infectivity via an interaction with cellular heparan sulfate. J. Virol. 74:6442-6457. http://dx.doi.org/10.1128/JVI.74.14.6442-6447.2000.
20. Feldman SA, Hendry RM, Beeler JA. 1999. Identification of a linear heparin binding domain for human respiratory syncytial virus attachment glycoprotein G. J. Virol. 73:6610-6617.
21. Tayyari F, Marchant D, Moraes TJ, Duan W, Mastrangelo P, Hegele RG. 2011. Identification of nucleolin as a cellular receptor for human respiratory syncytial virus. Nat. Med. 17:1132-1135. http://dx.doi.org/10.1038/nm.2444.
22. Bose S, Basu M, Banerjee AK. 2004. Role of nucleolin in human parainfluenza virus type 3 infection of human lung epithelial cells. J. Virol. 78:8146-8158. http://dx.doi.org/10.1128/JVI.78.15.8146-8158.2004.
23. Xiao X, Feng Y, Zhu Z, Dimitrov DS. 2011. Identification of a putative Crimean-Congo hemorrhagic fever virus entry factor. Biochem. Biophys. Res. Commun. 411:253-258. http://dx.doi.org/10.1016/j.bbrc.2011.06.109.
24. Thongtan T, Wikan N, Wintachai P, Rattanarungsan C, Srisomsap C, Cheepsunthorn P, Smith DR. 2012. Characterization of putative Japanese encephalitis virus receptor molecules on microglial cells. J. Med. Virol. 84:615-623. http://dx.doi.org/10.1002/jmv.23248.
25. Nisole S, Krust B, Callebaut C, Guichard G, Muller S, Briand JP, Hovanessian AG. 1999. The anti-HIV pseudopeptide HB-19 forms a complex with the cell-surface-expressed nucleolin independent of heparin sulfate proteoglycans. J. Biol. Chem. 274:27875-27884. http://dx.doi.org/10.1074/jbc.274.39.27875.
26. Rusnati M, Oreste P, Zoppetti G, Presta M. 2005. Biotechnological engineering of heparin/heparan sulphate: a novel area of multi-target drug discovery. Curr. Pharm. Des. 11:2489-2509. http://dx.doi.org/10.2174/ 1381612054367553.
27. Matos PM, Andreu D, Santos NC, Gutiérrez-Gallego R. 2014. Structural requirements of glycosaminoglycans for their interaction with HIV-1 envelope glycoprotein gp120. Arch. Virol. 159:555-560. http://dx.doi.org/10. 1007/s00705-013-1831-3.
28. Rusnati M, Coltrini D, Oreste P, Zoppetti G, Albini A, Noonan D, D'Adda di Fagagna F, Giacca M, Presta M. 1997. Interaction of HIV-1 Tat protein with heparin. Role of the backbone structure, sulfation, and size. J. Biol. Chem. 272:11313-11320.
29. Vervaeke P, Alen M, Noppen S, Schols D, Oreste P, Liekens S. 2013. Sulfated Escherichia coli K5 polysaccharide derivatives inhibit dengue virus infection of human microvascular endothelial cells by interacting with the viral envelope protein E domain III PLoS On. 8:e74035. http://dx.doi.org/10.1371/ journal.pone.0074035.
30. Bugatti A, Giagulli C, Urbinati C, Caccuri F, Chiodelli P, Oreste P, Fiorentini S, Orro A, Milanesi L, D'Ursi P, Caruso A, Rusnati M. 2013. Biochemical characterization of HIV-1 matrix protein p17 interaction with heparin. J. Biol. Chem. 288:1150-1161. http://dx.doi.org/10.1074/jbc.M112. 400077.
31. Patel M, Yanagishita M, Roderiquez G, Bou-Habib DC, Oravecz T, Hascall VC, Norcross MA. 1993. Cell-surface heparan sulfate proteoglycan mediates HIV-1 infection of T-cell lines. AIDS Res. Hum. Retroviruse. 9:167-174. http://dx.doi.org/10.1089/aid.1993.9.167.
32. Shieh MT, Dunn DW, Montgomery RI, Esko JD, Spear PG. 1992. Cell surface receptors for herpes simplex virus are heparan sulfate proteoglycans. J. Cell Biol. 116:1273-1281. http://dx.doi.org/10.1083/jcb.116.5.1273.
33. Giroglou T, Florin L, Schafer F, Streeck RE, Sapp M. 2001. Human papillomavirus infection requires cell surface heparan sulfate. J. Virol. 75:1565-1570. http://dx.doi.org/10.1128/JVI.75.3.1565-1570.2001.
34. Compton T. 2004. Receptors and immune sensors: the complex entry path of human cytomegalovirus. Trends Cell Biol. 14:5-8. http://dx.doi.org/10.1016/j. tcb.2003.10.009.
35. Chen Y, Maguire T, Hileman RE, Fromm JR, Esko J, Linhardt RJ, Marks RM. 1997. Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate. Nat. Med. 3:866-871. http://dx.doi.org/10.1038/nm0897-866.
36. Salvador B, Sexton NR, Carrion R, Jr, Nunneley J, Patterson JL, Steffen I, Lu K, Muench MO, Lembo D, Simmons G. 2013. Filoviruses utilize glycosaminoglycans for their attachment to target cells. J. Virol. 87:3295-3304. http://dx.doi.org/10.1128/JVI.01621-12.
37. Vicenzi E, Gatti A, Ghezzi S, Oreste P, Zoppetti G, Poli G. 2003. Broad spectrum inhibition of HIV-1 infection by sulfated K5 Escherichia coli polysaccharide derivatives. AID. 17:177-181. http://dx.doi.org/10.1097/00002030- 200301240-00006.
38. Pinna D, Oreste P, Coradin T, Kajaste-Rudnitski A, Ghezzi S, Zoppetti G, Rotola A, Argnani R, Poli G, Manservigi R, Vicenzi E. 2008. Inhibition of herpes simplex virus types 1 and 2 in vitro infection by sulfated derivatives of Escherichia coli K5 polysaccharide. Antimicrob. Agents Chemother. 52:3078-3084. http://dx.doi.org/10.1128/AAC.00359-08.
39. Lembo D, Donalisio M, Rusnati M, Bugatti A, Cornaglia M, Cappello P, Giovarelli M, Oreste P, Landolfo S. 2008. Sulfated K5 Escherichia coli polysaccharide derivatives as wide-range inhibitors of genital types of human papillomavirus. Antimicrob. Agents Chemother. 52:1374-1381. http://dx.doi.org/ 10.1128/AAC.01467-07.
40. Mercorelli B, Oreste P, Sinigalia E, Muratore G, Lembo D, Palù G, Loregian A. 2010. Sulfated derivatives of Escherichia coli K5 capsular polysaccharide are potent inhibitors of human cytomegalovirus. Antimicrob. Agents Chemother. 54:4561-4567. http://dx.doi.org/10.1128/AAC.00721-10.
41. Ludwig M, Enzenhofer E, Schneider S, Rauch M, Bodenteich A, Neumann K, Prieschl-Grassauer E, Grassauer A, Lion T, Mueller CA. 2013. Efficacy of a carrageenan nasal spray in patients with common cold: a randomized controlled trial. Respir. Res. 14:124. http://dx.doi.org/10.1186/1465-9921-14-124.
42. Marais D, Gawarecki D, Allan B, Ahmed K, Altini L, Cassim N, Gopolang F, Hoffman M, Ramjee G, Williamson AL. 2011. The effectiveness of Carraguard, a vaginal microbicide, in protecting women against high-risk human papillomavirus infection. Antivir. Ther. 16:1219-1226. http://dx.doi.org/10.3851/IMP1890.
43. Pirrone V, Wigdahl B, Krebs FC. 2011. The rise and fall of polyanionic inhibitors of the human immunodeficiency virus type 1. Antiviral Res. 90:168-182. http://dx.doi.org/10.1016/j.antiviral.2011.03.176.
44. Rusnati M, Vicenzi E, Donalisio M, Oreste P, Landolfo S, Lembo D. 2009. Sulfated K5 Escherichia coli polysaccharide derivatives: a novel class of candidate antiviral microbicides. Pharmacol. Ther. 123:310-322. http://dx.doi.org/10.1016/j.pharmthera.2009.05.001.
45. Urbinati C, Bugatti A, Oreste P, Zoppetti G, Waltenberger J, Mitola S, Ribatti D, Presta M, Rusnati M. 2004. Chemically sulfated Escherichia coli K5 polysaccharide derivatives as extracellular HIV-1 Tat protein antagonists. FEBS Lett. 568(1-3):171-177. http://dx.doi.org/10.1016/j.febslet.2004.05.033.
46. Moyes J, Cohen C, Pretorius M, Groome M, von Gottberg A, Wolter N, Walaza S, Haffejee S, Chhagan M, Naby F, Cohen AL, Tempia S, Kahn K, Dawood H, Venter M, Madhi SA, South African Severe Acute Respiratory Illness Surveillance Group. 2013. Epidemiology of respiratory syncytial virus-associated acute lower respiratory tract infection hospitalizations among HIV-infected and HIV-uninfected South African children, 2010-2011. J. Infect. Dis. 208:S217-S226. http://dx.doi.org/10.1093/infdis/jit479.
47. Leali D, Belleri M, Urbinati C, Coltrini D, Oreste P, Zoppetti G, Ribatti D, Rusnati M, Presta M. 2001. Fibroblast growth factor-2 antagonist activity and angiostatic capacity of sulfated Escherichia coli K5 polysaccharide derivatives. J. Biol. Chem. 276:37900-37908. http://dx.doi.org/10.1074/jbc. M105163200.
48. Casu B, Gennaro U. 1975. A conductimetric method for the determination of sulphate and carboxyl groups in heparin and other mucopolysaccharides. Carbohydr. Res. 39:168-176. http://dx.doi.org/10.1016/S0008-6215(00)82654-3.
49. Donalisio M, Rusnati M, Cagno V, Civra A, Bugatti A, Giuliani A, Pirri G, Volante M, Papotti M, Landolfo S, Lembo D. 2012. Inhibition of human respiratory syncytial virus infectivity by a dendrimeric heparan sulfate-binding peptide. Antimicrob. Agents Chemother. 56:5278-5288. http://dx.doi.org/10.1128/ AAC.00771-12.
50. Graham KL, Zeng W, Takada Y, Jackson DC, Coulson BS. 2004. Effects on rotavirus cell binding and infection of monomeric and polymeric peptides containing alpha2beta1 and alphaxbeta2 integrin ligand sequences. J. Virol. 78:11786-11797. http://dx.doi.org/10.1128/JVI.78.21.11786-11797.2004.
51. Ghosh T, Chattopadhyay K, Marschall M, Karmakar P, Mandal P, Ray B. 2009. Focus on antivirally active sulfated polysaccharides: from structureactivity analysis to clinical evaluation. Glycobiolog. 19:2-15. http://dx.doi.org/10. 1093/glycob/cwn092.
52. Morton CJ, Cameron R, Lawrence LJ, Lin B, Lowe M, Luttick A, Mason A, McKimm-Breschkin J, Parker MW, Ryan J, Smout M, Sullivan J, Tucker SP, Young PR. 2003. Structural characterization of respiratory syncytial virus fusion inhibitor escape mutants: homology model of the F protein and a syncytium formation assay. Virolog. 311:275-288. http://dx.doi.org/10.1016/S0042-6822(03) 00115-6.
53. Black CP. 2003. Systematic review of the biology and medical management of respiratory syncytial virus infection. Respir. Car. 48:209-231.
54. Lopez S, Arias CF. 2004. Multistep entry of rotavirus into cells: a Versaillesque dance. Trends Microbiol. 12:271-278. http://dx.doi.org/10.1016/j. tim.2004.04.003.
55. Hallak LK, Spillmann D, Collins PL, Peeples ME. 2000. Glycosaminoglycan sulfation requirements for respiratory syncytial virus infection. J. Virol. 74:10508-10513. http://dx.doi.org/10.1128/JVI.74.22.10508-10513.2000.
56. Hallak LK, Collins PL, Knudson W, Peeples ME. 2000. Iduronic acid containing glycosaminoglycans on target cells are required for efficient respiratory syncytial virus infection. Virolog. 271:264-275. http://dx.doi.org/10.1006/viro.2000.0293.
57. Kimura K, Ishioka K, Hashimoto K, Mori S, Suzutani T, Bowlin TL, Shigeta S. 2004. Isolation and characterization of NMSO3-resistant mutants of respiratory syncytial virus. Antiviral Res. 61:165-171. http://dx.doi.org/10. 1016/j.antiviral.2003.09.008.
58. Hosoya M, Balzarini J, Shigeta S, De Clercq E. 1991. Differential inhibitory effects of sulfated polysaccharides and polymers on the replication of various myxoviruses and retroviruses, depending on the composition of the target amino acid sequences of the viral envelope glycoproteins. Antimicrob. Agents Chemother. 35:2515-2520. http://dx.doi.org/10.1128/AAC.35.12.2515.
59. Rusnati M, Urbinati C. 2009. Polysulfated/sulfonated compounds for the development of drugs at the crossroad of viral infection and oncogenesis. Curr. Pharm. Des. 15:2946-2957. http://dx.doi.org/10.2174/138161209789058156.
60. Krusat T, Streckert HJ. 1997. Heparin-dependent attachment of respiratory syncytial virus (RSV) to host cells. Arch. Virol. 142:1247-1254. http://dx.doi.org/10.1007/s007050050156.
61. Bourgeois C, Bour JB, Lidholt K, Gauthray C, Pothier P. 1998. Heparinlike structures on respiratory syncytial virus are involved in its infectivity in vitro. J. Virol. 72:7221-7227.
62. Mulloy B, Forster MJ. 2000. Conformation and dynamics of heparin and heparan sulfate. Glycobiolog. 10:1147-1156. http://dx.doi.org/10.1093/glycob/10. 11.1147.
63. Delage G, Brochu P, Robillard L, Jasmin G, Joncas JH, Lapointe N. 1984. Giant cell pneumonia due to respiratory syncytial virus. Occurrence in severe combined immunodeficiency syndrome. Arch. Pathol. Lab. Med. 108:623-625.
64. Neilson KA, Yunis EJ. 1990. Demonstration of respiratory syncytial virus in an autopsy series. Pediatr. Pathol. 10:491-502. http://dx.doi.org/10.3109/ 15513819009067138.
65. Collins PL, Graham BS. 2008. Viral and host factors in human respiratory syncytial virus pathogenesis. J. Virol. 82:2040-2055. http://dx.doi.org/10.1128/ JVI.01625-07.
66. Richardson LS, Belshe RB, Sly DL, London WT, Prevar DA, Camargo E, Chanock RM. 1978. Experimental respiratory syncytial virus pneumonia in cebus monkeys. J. Med. Virol. 2:45-59. http://dx.doi.org/10.1002/jmv.1890020108.
67. Oreste P, Zoppetti G. 2012. Semi-synthetic heparinoids. Handb. Exp. Pharmacol. 207:403-422. http://dx.doi.org/10.1007/978-3-642-23056-1-18.
68. Collino M, Castiglia S, Manoni M, Salsini L, Chini J, Masini E, Fantozzi R. 2009. Effects of a semi-synthetic N-, O-sulfated glycosaminoglycan K5 polysaccharide derivative in a rat model of cerebral ischaemia/reperfusion injury. Thromb. Haemost. 102:837-845. http://dx.doi.org/10.1160/TH09-01-0012.
69. Zhang L, Peeples ME, Boucher RC, Collins PL, Pickles RJ. 2002. Respiratory syncytial virus infection of human airway epithelial cells is polarized, specific to ciliated cells, and without obvious cytopathology. J. Virol. 76:5654-5666. http://dx.doi.org/10.1128/JVI.76.11.5654-5666.2002.